Products for Research Use Only
RegisterLogin

SKLB06329

CAT: 0804-HY-178274Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-178274Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
SKLB06329 is a potent selective Type I PRMTs inhibitor. SKLB06329 shows good selectivity for PRMT6 (IC50 = 3.86 nM) over Type II/III PRMTs (PRMT5/7) and shows no significant inhibition against various lysine methyltransferases (PKMTs) . SKLB06329 significantly inhibits the proliferation of triple-negative breast cancer (TNBC) cells, induces apoptosis, and suppresses the expression of asymmetric dimethylarginine (ADMA) within cells. SKLB06329 can be used for triple-negative breast cancer research[1].
UNSPSC
12352005
Target
Apoptosis; Histone Methyltransferase
Related Pathways
Apoptosis; Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Smiles
CN(CC1=NNC2=CC=C(C=C21)C3=CC=C(C=C3)NS(=O)(C4CC4)=O)CCN
Molecular Formula
C20H25N5O2S
Molecular Weight
399.51
References & Citations
[1]Zhang Q, et al. Discovery of novel indazole derivatives as type I PRMTs inhibitors for the treatment of triple-negative breast cancer. Eur J Med Chem. 2025 Dec 15;300:118123.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
PRMT6

Alternative Products

CatalogName
GTR19273563-01SKLB06329

Popular Products